{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:25:15Z","timestamp":1789151115962,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00117-024-01312-1","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T10:01:58Z","timestamp":1715680918000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Das Prostatakarzinom-Screening\u00a0\u2013 aktueller \u00dcberblick","Prostate cancer screening\u2014current overview"],"prefix":"10.1007","volume":"64","author":[{"given":"Maxime","family":"De Vrieze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouvier","family":"Al-Monajjed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schimm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Boschheidgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"1312_CR1","unstructured":"Institut RKI (2021) Krebs Deutschl 2018(2017)"},{"issue":"7","key":"1312_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJ Bell","year":"2015","unstructured":"Bell\u00a0KJ et\u00a0al (2015) Prevalence of incidental prostate cancer: A\u00a0systematic review of autopsy studies. Int J Cancer 137(7):1749\u20131757","journal-title":"Int J Cancer"},{"key":"1312_CR3","first-page":"362","volume":"k3519","author":"D Ilic","year":"2018","unstructured":"Ilic\u00a0D et\u00a0al (2018) Prostate cancer screening with prostate-specific antigen (PSA) test: a\u00a0systematic review and meta-analysis. BMJ k3519:362","journal-title":"BMJ"},{"issue":"2","key":"1312_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/caac.20066","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf\u00a0AM et\u00a0al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60(2):70\u201398","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1312_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson\u00a0J et\u00a0al (2019) A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 76(1):43\u201351","journal-title":"Eur Urol"},{"key":"1312_CR6","doi-asserted-by":"crossref","unstructured":"de, V., II, et\u00a0al., A\u00a0Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol, 2023. 84(4): p.\u00a0426\u2013434.","DOI":"10.1016\/j.eururo.2023.03.016"},{"issue":"1","key":"1312_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","volume":"52","author":"J Hugosson","year":"2018","unstructured":"Hugosson\u00a0J et\u00a0al (2018) Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52(1):27\u201337","journal-title":"Scand J Urol"},{"issue":"4","key":"1312_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"123","author":"PF Pinsky","year":"2017","unstructured":"Pinsky\u00a0PF et\u00a0al (2017) Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15\u00a0years. Cancer 123(4):592\u2013599","journal-title":"Cancer"},{"issue":"3","key":"1312_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","volume":"68","author":"R Arnsrud Godtman","year":"2015","unstructured":"Arnsrud Godtman\u00a0R et\u00a0al (2015) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18\u00a0years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):354\u2013360","journal-title":"Eur Urol"},{"key":"1312_CR10","first-page":"381","volume":"e071082","author":"A Vickers","year":"2023","unstructured":"Vickers\u00a0A et\u00a0al (2023) Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ e071082:381","journal-title":"BMJ"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1741-7015-12-26","volume":"12","author":"AJ Vickers","year":"2014","unstructured":"Vickers\u00a0AJ et\u00a0al (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26","journal-title":"BMC Med"},{"key":"1312_CR12","unstructured":"GBA, Richtlinie des Gemeinsamen Bundesausschusses \u00fcber die Fr\u00fcherkennung von Krebserkrankungen. 2020."},{"key":"1312_CR13","doi-asserted-by":"crossref","unstructured":"Starker, A. and A.C.\u00a0Sass, [Participation in cancer screening in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013. 56(5\u20136): p.\u00a0858\u201367.","DOI":"10.1007\/s00103-012-1655-4"},{"key":"1312_CR14","unstructured":"(1971) Richtlinien des Bundesausschusses der \u00c4rzte und Krankenkassen \u00fcber die Fr\u00fcherkennung von Krebserkrankungen (Krebsfr\u00fcherkennungs-Richtlinien). Dtsch \u00c4rztebl 68(25):1914\u20131916"},{"issue":"2","key":"1312_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"L Naji","year":"2018","unstructured":"Naji\u00a0L et\u00a0al (2018) Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A\u00a0Systematic Review and Meta-Analysis. Ann Fam Med 16(2):149\u2013154","journal-title":"Ann Fam Med"},{"key":"1312_CR16","doi-asserted-by":"crossref","unstructured":"Schroder, F.H., et\u00a0al., Evaluation of the digital rectal examination as a\u00a0screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J\u00a0Natl Cancer Inst, 1998. 90(23): p.\u00a01817\u201323.","DOI":"10.1093\/jnci\/90.23.1817"},{"key":"1312_CR17","unstructured":"Krilaviciute A et\u00a0al (2023) Digital Rectal Examination Is Not a\u00a0Useful Screening Test for Prostate Cancer. Eur. Urol Oncol"},{"issue":"3","key":"1312_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.eururo.2020.12.010","volume":"79","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel\u00a0H et\u00a0al (2021) Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 79(3):327\u2013329","journal-title":"Eur Urol"},{"issue":"6","key":"1312_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","volume":"80","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel\u00a0H et\u00a0al (2021) Prostate-specific Antigen Testing as Part of a\u00a0Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 80(6):703\u2013711","journal-title":"Eur Urol"},{"key":"1312_CR20","doi-asserted-by":"crossref","unstructured":"Majek, O., et\u00a0al., How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration. Eur Urol Open Sci, 2023. 53: p.\u00a0106\u2013108.","DOI":"10.1016\/j.euros.2023.05.011"},{"key":"1312_CR21","doi-asserted-by":"crossref","unstructured":"Beyer K et\u00a0al (2024) Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE\u2011U Consortium. J\u00a0Pers Med 14(1)","DOI":"10.3390\/jpm14010084"},{"key":"1312_CR22","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.2. 2021."},{"key":"1312_CR23","series-title":"Milan","volume-title":"Edn. presented at the","author":"EAU Guidelines","year":"2023","unstructured":"Guidelines\u00a0EAU (2023) Edn. presented at the. Milan, Bd. 2023. EAU, Annual Congress"},{"issue":"CD012663","key":"1312_CR24","first-page":"4","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost\u00a0FH et\u00a0al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4(CD012663):4","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"1312_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V et\u00a0al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N\u00a0Engl J Med 378(19):1767\u20131777","journal-title":"N Engl J Med"},{"issue":"4","key":"1312_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest\u00a0M et\u00a0al (2019) Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A\u00a0Large Prospective Multicenter Clinical Study. Eur Urol 75(4):570\u2013578","journal-title":"Eur Urol"},{"issue":"1","key":"1312_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouviere","year":"2019","unstructured":"Rouviere\u00a0O et\u00a0al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a\u00a0prospective, multicentre, paired diagnostic study. Lancet Oncol 20(1):100\u2013109","journal-title":"Lancet Oncol"},{"issue":"4","key":"1312_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","volume":"75","author":"O Wegelin","year":"2019","unstructured":"Wegelin\u00a0O et\u00a0al (2019) The FUTURE Trial: A\u00a0Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol 75(4):582\u2013590","journal-title":"Eur Urol"},{"key":"1312_CR29","doi-asserted-by":"crossref","unstructured":"Exterkate, L., et\u00a0al., Is There Still a\u00a0Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate? Eur Urol Oncol, 2020. 3(2): p.\u00a0216\u2013223.","DOI":"10.1016\/j.euo.2019.06.005"},{"issue":"10","key":"1312_CR30","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund\u00a0M et\u00a0al (2021) MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N\u00a0Engl J Med 385(10):908\u2013920","journal-title":"N Engl J Med"},{"issue":"9","key":"1312_CR31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstrom","year":"2021","unstructured":"Nordstrom\u00a0T et\u00a0al (2021) Prostate cancer screening using a\u00a0combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a\u00a0prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol 22(9):1240\u20131249","journal-title":"Lancet Oncol"},{"issue":"2","key":"1312_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","volume":"55","author":"K Kohestani","year":"2021","unstructured":"Kohestani\u00a0K et\u00a0al (2021) The GOTEBORG prostate cancer screening 2\u00a0trial: a\u00a0prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol 55(2):116\u2013124","journal-title":"Scand J Urol"},{"issue":"23","key":"1312_CR33","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson\u00a0J et\u00a0al (2022) Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N\u00a0Engl J Med 387(23):2126\u20132137","journal-title":"N Engl J Med"},{"issue":"3","key":"1312_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey\u00a0B et\u00a0al (2019) Prostate Imaging Reporting and Data System Version\u00a02.1: 2019 Update of Prostate Imaging Reporting and Data System Version\u00a02. Eur Urol 76(3):340\u2013351","journal-title":"Eur Urol"},{"issue":"1","key":"1312_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/JU.0000000000000757","volume":"204","author":"MA Pagniez","year":"2020","unstructured":"Pagniez\u00a0MA et\u00a0al (2020) Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Urol 204(1):24\u201332","journal-title":"J Urol"},{"issue":"7","key":"1312_CR36","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00261-023-03929-7","volume":"48","author":"R Nicola","year":"2023","unstructured":"Nicola\u00a0R, Bittencourt\u00a0LK (2023) PI-RADS 3\u00a0lesions: a\u00a0critical review and discussion of how to improve management. Abdom Radiol (ny) 48(7):2401\u20132405","journal-title":"Abdom Radiol (ny)"},{"issue":"3","key":"1312_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s10278-019-00312-1","volume":"33","author":"AS Becker","year":"2020","unstructured":"Becker\u00a0AS et\u00a0al (2020) Interactive, Up-to-date Meta-Analysis of MRI in the Management of Men with Suspected Prostate Cancer. J\u00a0Digit Imaging 33(3):586\u2013594","journal-title":"J Digit Imaging"},{"key":"1312_CR38","doi-asserted-by":"crossref","unstructured":"Boesen, L., et\u00a0al., Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open, 2018. 1(2): p. e180219.","DOI":"10.1001\/jamanetworkopen.2018.0219"},{"issue":"5","key":"1312_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","volume":"76","author":"M van der Leest","year":"2019","unstructured":"van der Leest\u00a0M et\u00a0al (2019) High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol 76(5):574\u2013581","journal-title":"Eur Urol"},{"issue":"1","key":"1312_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/AJR.20.24268","volume":"216","author":"IG Schoots","year":"2021","unstructured":"Schoots\u00a0IG et\u00a0al (2021) PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol 216(1):3\u201319","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"1312_CR41","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.1007\/s00330-021-07907-9","volume":"31","author":"J Wallstrom","year":"2021","unstructured":"Wallstrom\u00a0J et\u00a0al (2021) Bi- or multiparametric MRI in a\u00a0sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2\u00a0trial. Eur Radiol 31(11):8692\u20138702","journal-title":"Eur Radiol"},{"key":"1312_CR42","doi-asserted-by":"crossref","unstructured":"Boschheidgen M et\u00a0al (2023) Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol","DOI":"10.1016\/j.eururo.2023.09.027"},{"issue":"3","key":"1312_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","volume":"7","author":"D Eldred-Evans","year":"2021","unstructured":"Eldred-Evans\u00a0D et\u00a0al (2021) Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. JAMA Oncol 7(3):395\u2013402","journal-title":"JAMA Oncol"},{"issue":"4","key":"1312_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse\u00a0A et\u00a0al (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011\u20131011","journal-title":"Cell"},{"issue":"6","key":"1312_CR45","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","volume":"34","author":"C Gerhauser","year":"2018","unstructured":"Gerhauser\u00a0C et\u00a0al (2018) Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell 34(6):996\u20131011.e8","journal-title":"Cancer Cell"},{"key":"1312_CR46","doi-asserted-by":"crossref","unstructured":"Eickelschulte, S., et\u00a0al., Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. Cancers 2022, Vol.\u00a014, Page 6094, 2022. 14(24): p.\u00a06094\u20136094.","DOI":"10.3390\/cancers14246094"},{"issue":"2","key":"1312_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner\u00a0MC et\u00a0al (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18(2):79\u201392","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1312_CR48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks\u00a0D et\u00a0al (2014) Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 8(3):798\u2013806","journal-title":"Cell Rep"},{"key":"1312_CR49","doi-asserted-by":"crossref","unstructured":"Bryant RJ et\u00a0al (2015) Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. JNCI J Natl Cancer Inst 107(7)","DOI":"10.1093\/jnci\/djv095"},{"issue":"2","key":"1312_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1756287213513488","volume":"6","author":"S Loeb","year":"2014","unstructured":"Loeb\u00a0S, Catalona\u00a0WJ (2014) The Prostate Health Index: a\u00a0new test for the detection of prostate cancer. Ther Adv Urol 6(2):74\u201377","journal-title":"Ther Adv Urol"},{"issue":"6","key":"1312_CR51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.eururo.2017.03.025","volume":"72","author":"EA Klein","year":"2017","unstructured":"Klein\u00a0EA et\u00a0al (2017) The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a\u00a0Concentration-based Assay of Total Prostate-specific Antigen: A\u00a0Preliminary Report. Eur Urol 72(6):942\u2013949","journal-title":"Eur Urol"},{"issue":"5","key":"1312_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste\u00a0L et\u00a0al (2016) Detection of High-grade Prostate Cancer Using a\u00a0Urinary Molecular Biomarker-Based Risk Score. Eur Urol 70(5):740\u2013748","journal-title":"Eur Urol"},{"issue":"4","key":"1312_CR53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","volume":"23","author":"R Tutrone","year":"2020","unstructured":"Tutrone\u00a0R et\u00a0al (2020) Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a\u00a0PSA 2\u201310\u202fng\/mL. Prostate Cancer Prostatic Dis 23(4):607\u2013614","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1312_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins\u00a0SA et\u00a0al (2016) Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol 70(1):45\u201353","journal-title":"Eur Urol"},{"issue":"10","key":"1312_CR55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14737140.2018.1502086","volume":"18","author":"G Ploussard","year":"2018","unstructured":"Ploussard\u00a0G, de la Taille\u00a0A (2018) The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection. Expert Rev Anticancer Ther 18(10):1013\u20131020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"1312_CR56","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg\u00a0H et\u00a0al (2015) Prostate cancer screening in men aged 50\u201369\u00a0years (STHLM3): a\u00a0prospective population-based diagnostic study. Lancet Oncol 16(16):1667\u20131676","journal-title":"Lancet Oncol"},{"issue":"3","key":"1312_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41391-022-00537-2","volume":"25","author":"AP Alarcon-Zendejas","year":"2022","unstructured":"Alarcon-Zendejas\u00a0AP et\u00a0al (2022) The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. Prostate Cancer Prostatic Dis 25(3):431\u2013443","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1312_CR58","first-page":"346","volume":"f2023","author":"AJ Vickers","year":"2013","unstructured":"Vickers\u00a0AJ et\u00a0al (2013) Strategy for detection of prostate cancer based on relation between prostate specific antigen at age\u00a040\u201355 and long term risk of metastasis: case-control study. BMJ f2023:346","journal-title":"BMJ"},{"issue":"11","key":"1312_CR59","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C et\u00a0al (2022) A\u00a0randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer 150(11):1861\u20131869","journal-title":"Int J Cancer"},{"issue":"12","key":"1312_CR60","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1634\/theoncologist.2009-0132","volume":"14","author":"A Brandt","year":"2009","unstructured":"Brandt\u00a0A et\u00a0al (2009) Age at diagnosis and age at death in familial prostate cancer. Oncologist 14(12):1209\u20131217","journal-title":"Oncologist"},{"issue":"6","key":"1312_CR61","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page\u00a0EC et\u00a0al (2019) Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA\u00a02 Mutation Carriers. Eur Urol 76(6):831\u2013842","journal-title":"Eur Urol"},{"issue":"11","key":"1312_CR62","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","volume":"22","author":"EK Bancroft","year":"2021","unstructured":"Bancroft\u00a0EK et\u00a0al (2021) A\u00a0prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 22(11):1618\u20131631","journal-title":"Lancet Oncol"},{"issue":"17","key":"1312_CR63","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC et\u00a0al (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N\u00a0Engl J Med 388(17):1547\u20131558","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s00117-024-01329-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000}}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01312-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-024-01312-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01312-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:02:55Z","timestamp":1718611375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-024-01312-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s00117-024-01312-1","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00117-024-01329-6","URL":"https:\/\/doi.org\/10.1007\/s00117-024-01329-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0De Vrieze, A.\u00a0H\u00fcbner, R.\u00a0Al-Monajjed, P.\u00a0Albers, J.P.\u00a0Radtke, L.\u00a0Schimm\u00f6ller und M.\u00a0Boschheidgen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}